HUTCHMED

HUTCHMED is an innovative, commercial-stage biopharmaceutical company dedicated to discovering and globally developing targeted therapies and immunotherapies for the treatment of cancer and immune diseases. We are one of the first companies in China to focus on global new drug research and development. Over the past two decades, we have built a fully integrated R&D platform with world-class discovery and development capabilities. As of 2020, we have an internal scientific team of more than 600 professionals and ten clinical-stage drug candidates in clinical trials worldwide. We have also developed a profitable commercial platform with deep pan-China market access that produces, markets, and distributes prescription drugs and consumer health products, as well as our two novel oncology products already on the market in China – ELUNATE® (fruquintinib capsules) and SULANDA® (surufatinib capsules). We are expanding the geographic scope of our commercial operations to include the United States and Europe.